JP2020503265A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503265A5 JP2020503265A5 JP2019527321A JP2019527321A JP2020503265A5 JP 2020503265 A5 JP2020503265 A5 JP 2020503265A5 JP 2019527321 A JP2019527321 A JP 2019527321A JP 2019527321 A JP2019527321 A JP 2019527321A JP 2020503265 A5 JP2020503265 A5 JP 2020503265A5
- Authority
- JP
- Japan
- Prior art keywords
- raav
- vector according
- pharmaceutical composition
- virus
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022112657A JP2022137210A (ja) | 2016-11-17 | 2022-07-13 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
| JP2024008380A JP2024045289A (ja) | 2016-11-17 | 2024-01-24 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423618P | 2016-11-17 | 2016-11-17 | |
| US62/423,618 | 2016-11-17 | ||
| PCT/US2017/062371 WO2018094251A1 (en) | 2016-11-17 | 2017-11-17 | Intrathecal delivery of recombinant adeno-associated virus encoding methyl-cpg binding protein 2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022112657A Division JP2022137210A (ja) | 2016-11-17 | 2022-07-13 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503265A JP2020503265A (ja) | 2020-01-30 |
| JP2020503265A5 true JP2020503265A5 (enExample) | 2022-04-13 |
| JP7106534B2 JP7106534B2 (ja) | 2022-07-26 |
Family
ID=62145776
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019527321A Active JP7106534B2 (ja) | 2016-11-17 | 2017-11-17 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
| JP2022112657A Pending JP2022137210A (ja) | 2016-11-17 | 2022-07-13 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
| JP2024008380A Pending JP2024045289A (ja) | 2016-11-17 | 2024-01-24 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022112657A Pending JP2022137210A (ja) | 2016-11-17 | 2022-07-13 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
| JP2024008380A Pending JP2024045289A (ja) | 2016-11-17 | 2024-01-24 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11583564B2 (enExample) |
| EP (1) | EP3541429A4 (enExample) |
| JP (3) | JP7106534B2 (enExample) |
| KR (1) | KR102641846B1 (enExample) |
| CN (2) | CN118490845A (enExample) |
| AU (3) | AU2017362491B2 (enExample) |
| BR (1) | BR112019009834B1 (enExample) |
| CA (1) | CA3044291A1 (enExample) |
| CL (1) | CL2019001354A1 (enExample) |
| IL (2) | IL266678B2 (enExample) |
| MA (1) | MA46863A (enExample) |
| MX (1) | MX2019005874A (enExample) |
| SA (1) | SA519401806B1 (enExample) |
| SG (1) | SG10202105090WA (enExample) |
| WO (1) | WO2018094251A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7106534B2 (ja) * | 2016-11-17 | 2022-07-26 | ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
| WO2019094253A1 (en) | 2017-11-08 | 2019-05-16 | Avexis Inc. | Means and method for preparing viral vectors and uses of same |
| EP3801638A1 (en) | 2018-06-08 | 2021-04-14 | Novartis AG | Cell-based assay for measuring drug product potency |
| CA3129077A1 (en) * | 2019-02-04 | 2020-08-13 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus delivery of cln3 polynucleotide |
| CA3158131A1 (en) * | 2019-10-18 | 2021-04-22 | Nicolas Sebastien Wein | Materials and methods for the treatment of disorders associated mutations in the irf2bpl gene |
| AU2020385387A1 (en) * | 2019-11-22 | 2022-06-02 | Fondazione Irccs Ca' Granda Ospedale Maggiore Foliclinico | Materials and methods for treatment of disorders associated with the IGHMBP2 gene |
| WO2022221424A1 (en) | 2021-04-13 | 2022-10-20 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus encoding methyl-cpg binding protein 2 for treating pitt hopkins syndrome via intrathecal delivery |
| EP4715058A1 (en) * | 2023-05-15 | 2026-03-25 | Genecombio Ltd. | Gene therapy for rett syndrome |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| PT728214E (pt) | 1993-11-09 | 2004-11-30 | Ohio Med College | Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado |
| WO1995013365A1 (en) | 1993-11-09 | 1995-05-18 | Targeted Genetics Corporation | Generation of high titers of recombinant aav vectors |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| RU2273645C9 (ru) | 1994-08-17 | 2006-11-27 | Дзе Рокефеллер Юниверсити | Полипептид ожирения (ов)(варианты), его аналог (варианты) и слитый белок (варианты), изолированная молекула нуклеиновой кислоты, молекула днк, рекомбинантный вектор клонирования, рекомбинантный вектор экспрессии, фармацевтическая композиция, моноклональное и поликлональное антитело |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| CA2207927A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
| FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
| WO1997008298A1 (en) | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
| US6632670B1 (en) | 1995-09-08 | 2003-10-14 | Genzyme Corporation | AAV vectors for gene therapy |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| JP2001500497A (ja) | 1996-09-06 | 2001-01-16 | トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスに指図される遺伝子治療の方法 |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| DK1009808T3 (da) | 1997-09-05 | 2013-01-21 | Genzyme Corp | Fremgangsmåder til generering af hjælper-frie præparater af rekombinante aav-vektorer med høj titer |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| GB9916702D0 (en) | 1999-07-16 | 1999-09-15 | Cantab Pharma Res | Virus vectors and preparations and their use |
| US7056502B2 (en) | 2000-04-28 | 2006-06-06 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids |
| DK2573170T3 (en) | 2001-12-17 | 2018-04-09 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 9, vectors containing them, and their use |
| US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| CA2554380C (en) | 2004-02-17 | 2015-05-19 | The Hospital For Sick Children | Mecp2e1 gene |
| EP2066791B1 (en) * | 2006-10-03 | 2012-09-12 | Genzyme Corporation | Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders |
| TWI478937B (zh) | 2008-01-15 | 2015-04-01 | Abbvie Inc | 改良之哺乳動物表現載體及其用途 |
| US20090246768A1 (en) | 2008-02-15 | 2009-10-01 | Sawalha Amr H | Predicting and Diagnosing Patients With Autoimmune Disease |
| US9415121B2 (en) | 2008-12-19 | 2016-08-16 | Nationwide Children's Hospital | Delivery of MECP2 polynucleotide using recombinant AAV9 |
| US11219696B2 (en) * | 2008-12-19 | 2022-01-11 | Nationwide Children's Hospital | Delivery of polynucleotides using recombinant AAV9 |
| DE102012007232B4 (de) | 2012-04-07 | 2014-03-13 | Susanne Weller | Verfahren zur Herstellung von rotierenden elektrischen Maschinen |
| JP2015092462A (ja) | 2013-09-30 | 2015-05-14 | Tdk株式会社 | 正極及びそれを用いたリチウムイオン二次電池 |
| WO2015141521A1 (ja) | 2014-03-21 | 2015-09-24 | 株式会社日立国際電気 | 基板処理装置、半導体装置の製造方法及び記録媒体 |
| JP6197169B2 (ja) | 2014-09-29 | 2017-09-20 | 東芝メモリ株式会社 | 半導体装置の製造方法 |
| WO2016100575A1 (en) | 2014-12-16 | 2016-06-23 | Board Of Regents Of The University Of Nebraska | Gene therapy for juvenile batten disease |
| JP7106534B2 (ja) * | 2016-11-17 | 2022-07-26 | ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
| US11680275B2 (en) * | 2017-06-06 | 2023-06-20 | University Of Massachusetts | Self-regulating AAV vectors for safe expression of MeCP2 in rett syndrome |
-
2017
- 2017-11-17 JP JP2019527321A patent/JP7106534B2/ja active Active
- 2017-11-17 AU AU2017362491A patent/AU2017362491B2/en active Active
- 2017-11-17 EP EP17872045.4A patent/EP3541429A4/en active Pending
- 2017-11-17 CN CN202410270436.6A patent/CN118490845A/zh active Pending
- 2017-11-17 MX MX2019005874A patent/MX2019005874A/es unknown
- 2017-11-17 MA MA046863A patent/MA46863A/fr unknown
- 2017-11-17 IL IL266678A patent/IL266678B2/en unknown
- 2017-11-17 IL IL322146A patent/IL322146A/en unknown
- 2017-11-17 KR KR1020197017104A patent/KR102641846B1/ko active Active
- 2017-11-17 BR BR112019009834-8A patent/BR112019009834B1/pt active IP Right Grant
- 2017-11-17 CN CN201780072105.XA patent/CN110325219B/zh active Active
- 2017-11-17 CA CA3044291A patent/CA3044291A1/en active Pending
- 2017-11-17 WO PCT/US2017/062371 patent/WO2018094251A1/en not_active Ceased
- 2017-11-17 SG SG10202105090WA patent/SG10202105090WA/en unknown
- 2017-11-17 US US16/461,837 patent/US11583564B2/en active Active
-
2019
- 2019-05-17 CL CL2019001354A patent/CL2019001354A1/es unknown
- 2019-05-17 SA SA519401806A patent/SA519401806B1/ar unknown
-
2022
- 2022-07-13 JP JP2022112657A patent/JP2022137210A/ja active Pending
-
2023
- 2023-01-02 US US18/149,151 patent/US12357663B2/en active Active
- 2023-04-28 AU AU2023202598A patent/AU2023202598B2/en active Active
-
2024
- 2024-01-24 JP JP2024008380A patent/JP2024045289A/ja active Pending
-
2025
- 2025-06-20 US US19/244,103 patent/US20250312400A1/en active Pending
-
2026
- 2026-01-13 AU AU2026200191A patent/AU2026200191A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503265A5 (enExample) | ||
| JP7607007B2 (ja) | 変異ａａｖ、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法 | |
| JP7818558B2 (ja) | 修飾された第ｉｘ因子、並びに、細胞、器官及び組織への遺伝子導入のための組成物、方法及び使用 | |
| US10413598B2 (en) | Factor IX gene therapy | |
| JP2021510528A (ja) | 遺伝子治療のための修飾ｒＡＡＶキャプシドタンパク質 | |
| JP2020514286A5 (enExample) | ||
| JP7106534B2 (ja) | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 | |
| WO2014016580A1 (en) | Transgene expression | |
| JP2025069161A (ja) | ９番染色体オープンリーディングフレーム７２遺伝子発現のモジュレーターおよびその使用 | |
| JP2022513318A5 (enExample) | ||
| IL262459B2 (en) | Compositions and methods for increased gene expression of pklr for the treatment of pyruvate kinase deficiency | |
| JP2022500353A (ja) | Ｉｇｆ−１−暗号化ｄｎａ作製物及びｈｇｆ−暗号化ｄｎａ作製物を用いた神経病症治療 | |
| JP2023534293A5 (enExample) | ||
| CN119255814A (zh) | 脑中bag3和蛋白质的质量控制 | |
| US20200079824A1 (en) | Gene therapy for tuberous sclerosis | |
| JP2022530359A5 (enExample) | ||
| US20240335506A1 (en) | Aqp1 gene therapy to prevent radiation induced salivary hypofunction | |
| JP2020524132A5 (enExample) | ||
| CA3146364A1 (en) | One-step gene therapy for duchenne muscular dystrophy via gene replacement and anti-inflammation | |
| JP2025526697A (ja) | 組換えウイルスベクターに関連する有害作用の予防または緩和 | |
| JP2024505257A (ja) | 神経セロイドリポフスチン症の遺伝子治療 | |
| HK40104471A (zh) | 用於目的基因的表达盒及其应用 | |
| RU2023103235A (ru) | Модифицированный фактор ix, а также композиции, способы и варианты применения переноса генов в клетки, органы и ткани | |
| NZ748736A (en) | Treatment of complement-mediated disorders | |
| NZ724165B2 (en) | Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency |